Ozempic Appetite & Cravings Changes: What the Clinical Evidence Shows

Does Ozempic change appetite?

Ozempic is semaglutide, a GLP-1 receptor agonist injected once a week. Its approved uses are blood sugar control in adults with type 2 diabetes, reduction of major cardiovascular events in adults with type 2 diabetes and established cardiovascular disease, and reduction of kidney and cardiovascular risk in adults with type 2 diabetes and chronic kidney disease. It has no weight-loss indication [4].

Appetite is part of how the drug works rather than an incidental finding. In its 2025 review of semaglutide safety, the European Medicines Agency's safety committee described semaglutide as regulating appetite by increasing a person's feelings of fullness while reducing food intake, hunger and cravings [1].

Semaglutide is a GLP-1 analogue with 94% sequence homology to human GLP-1. It binds and activates the GLP-1 receptor, including receptors in brain areas that regulate appetite and calorie intake, and it slows gastric emptying.

What the trials actually measured

Two small placebo-controlled trials measured appetite and eating directly. Neither used the 0.5 mg or 2 mg Ozempic doses.

12 weeks of treatment escalated to 1 mg (30 adults)

This was a randomized, double-blind, placebo-controlled, two-period crossover trial in 30 adults with obesity. Participants received 12 weeks of once-weekly semaglutide, dose-escalated to 1.0 mg [2].

After a standard breakfast, people ate 1,255 kJ less at an unlimited lunch on semaglutide than on placebo (P<0.0001), ate less at the evening meal (P=0.04) and at snacks (P=0.003), and ate 24% less across all the unlimited meals over the day (-3,036 kJ; P<0.0001) [2].

Fasting appetite suppression scores improved, and participants reported less hunger and fewer food cravings, better control of eating and a lower preference for high-fat foods. Nausea ratings were similar on semaglutide and placebo. Body weight fell by 5.0 kg, mostly fat mass, and resting metabolic rate adjusted for lean body mass did not differ between treatments [2].

20 weeks of treatment escalated to 2.4 mg (72 adults)

This was a double-blind, parallel-group trial in 72 adults with obesity, with semaglutide dose-escalated to 2.4 mg once weekly over 20 weeks [3]. That is the Wegovy maintenance dose, not an Ozempic dose.

Energy eaten at an unlimited lunch was 35% lower with semaglutide than placebo (1,736 versus 2,676 kJ; difference -940 kJ; P<0.0001). Hunger and prospective food consumption fell, and fullness and satiety rose (all P<0.02). On the Control of Eating Questionnaire, participants reported better control of eating and fewer or weaker food cravings (P<0.05). Weight fell 9.9% versus 0.4% on placebo [3].

That trial also tested gastric emptying with a paracetamol absorption test. Absorption over the first 5 hours was 8% higher on semaglutide (P=0.005), but the difference was not significant once body weight was accounted for (P=0.12), and the authors concluded there was no evidence of delayed gastric emptying at week 20 on that indirect measure [3].

What about the 0.5 mg and 2 mg doses?

Ozempic's label starts at 0.25 mg weekly for 4 weeks, then 0.5 mg, then 1 mg and 2 mg if more blood sugar control is needed, with at least 4 weeks on each step; 2 mg is the maximum weekly dose [4]. The appetite trials above reported hunger and energy intake only after escalation to 1 mg or 2.4 mg.

The 2 mg dose was compared with 1 mg in SUSTAIN FORTE, a 40-week trial in 961 adults with type 2 diabetes on metformin. HbA1c fell 2.2 percentage points with 2 mg versus 1.9 with 1 mg, and weight fell 6.9 kg versus 6.0 kg [6]. In the Ozempic label, gastrointestinal reactions in the 959-patient trial of 1 mg versus 2 mg (40 weeks) occurred in 34% on 2 mg versus 30.8% on 1 mg, with no new safety signals [4].

For comparison with another drug, SUSTAIN 7 randomized 1,201 adults with type 2 diabetes to semaglutide or dulaglutide for 40 weeks; weight fell 6.5 kg on semaglutide 1 mg versus 3.0 kg on dulaglutide 1.5 mg [7]. That trial compared weight, not measured hunger.

Which cravings change?

In the 1 mg trial, participants reported a lower preference for high-fat foods [2]. In the 2.4 mg trial, they reported fewer or weaker food cravings on the Control of Eating Questionnaire [3].

Brain imaging work with a different GLP-1 receptor agonist points the same direction. In a randomized, placebo-controlled crossover study of 48 people, intravenous exenatide reduced food intake and reduced brain responses to pictures of food in the insula, amygdala, putamen and orbitofrontal cortex; a GLP-1 receptor blocker largely reversed those effects [8]. That study used exenatide, not semaglutide.

What happens when treatment stops?

The appetite trials measured hunger ratings and craving questionnaires after 12 and 20 weeks of treatment [2][3]. What happens after treatment stops has been measured for weight, at the 2.4 mg dose. In STEP 4, 803 adults who had lost a mean 10.6% of body weight over a 20-week run-in were randomized to continue semaglutide 2.4 mg or switch to placebo for 48 weeks. From week 20 to week 68, the continuing group lost a further 7.9% while the placebo group gained 6.9%, a difference of 14.8 percentage points [9].

The STEP 1 off-treatment extension included 327 participants. Those who had received semaglutide had lost a mean 17.3% of body weight by week 68 and regained 11.6 percentage points within a year of stopping, leaving a net loss of 5.6% from baseline at week 120 versus 0.1% on placebo [5].

Nausea, appetite and what the label lists

Nausea is the most common adverse reaction in the Ozempic label. In pooled placebo-controlled trials in type 2 diabetes, nausea occurred in 6.1% on placebo, 15.8% on 0.5 mg and 20.3% on 1 mg; vomiting in 2.3%, 5% and 9.2%; diarrhea in 1.9%, 8.5% and 8.8%; abdominal pain in 4.6%, 7.3% and 5.7%; and constipation in 1.5%, 5% and 3.1% [4]. Any gastrointestinal reaction occurred in 15.3%, 32.7% and 36.4%, and 0.4%, 3.1% and 3.8% stopped treatment for a gastrointestinal reason. Most reports of nausea, vomiting and diarrhea occurred during dose escalation [4].

In the 12-week crossover trial at 1 mg, nausea ratings were similar on semaglutide and placebo while hunger and energy intake were lower [2].

One label detail matters if you compare formulations. In the oral semaglutide tablets label, decreased appetite is listed among common adverse reactions, at 1% on placebo, 6% on 7 mg and 9% on 14 mg, and that label's safety data come from Rybelsus trials [10]. In the Ozempic injection label's table of reactions occurring in at least 5% of patients, the listed reactions are nausea, vomiting, diarrhea, abdominal pain and constipation; decreased appetite is not among them [4].

What the label says to watch for

The Ozempic label reports severe gastrointestinal adverse reactions in 0.4% of patients on 0.5 mg and 0.8% on 1 mg versus 0% on placebo, and says the drug is not recommended in patients with severe gastroparesis [4]. The label says to discontinue Ozempic if pancreatitis is suspected, and lists acute gallbladder disease and acute kidney injury from volume depletion among its warnings [4]. It also says the risk of low blood sugar rises when semaglutide is used with insulin or an insulin secretagogue such as a sulfonylurea [4].